ERS Genomics signs CRISPR patent deal on industrial applications
16-10-2018
ERS extends CRISPR influence with two licensing deals
20-09-2018
ralwel / iStockphoto.com
The company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, ERS Genomics, has signed a patent licensing deal with DefiniGEN, a spin-out from the University of Cambridge, UK.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
ERS Genomics, patent licence, CRISPR, patent, Cambridge University, DefiniGEN
